Lipocine Announces Initiation Of Phase 3 BLOOM Study Of Oral Brexanolone LPCN 1154 In Postpartum Depression, Planning About 120 Participants; First Dosing Expected Early Q4 2026

Loading news article.

Lipocine Announces Initiation Of Phase 3 BLOOM Study Of Oral Brexanolone LPCN 1154 In Postpartum Depression, Planning About 120 Participants; First Dosing Expected Early Q4 2026 | WAPE

Lipocine Announces Initiation Of Phase 3 BLOOM Study Of Oral Brexanolone LPCN 1154 In Postpartum Depression, Planning About 120 Participants; First Dosing Expected Early Q4 2026

Article summary

Related companies

Analyzed by WAPE AI.

Comments —